These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21744089)

  • 1. A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems.
    Cox TF; Ranganath L
    J Inherit Metab Dis; 2011 Dec; 34(6):1153-62. PubMed ID: 21744089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of alkaptonuria revisited: analyses based on scoring systems.
    Ranganath LR; Cox TF
    J Inherit Metab Dis; 2011 Dec; 34(6):1141-51. PubMed ID: 21748407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    J Inherit Metab Dis; 2021 May; 44(3):666-676. PubMed ID: 33452825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients.
    Ranganath LR; Heseltine T; Khedr M; Fisher MF
    Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria.
    Arnoux JB; Le Quan Sang KH; Brassier A; Grisel C; Servais A; Wippf J; Dubois S; Sireau N; Job-Deslandre C; Ranganath L; de Lonlay P
    J Inherit Metab Dis; 2015 Sep; 38(5):791-6. PubMed ID: 25860819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
    Tinti L; Spreafico A; Braconi D; Millucci L; Bernardini G; Chellini F; Cavallo G; Selvi E; Galeazzi M; Marcolongo R; Gallagher JA; Santucci A
    J Cell Physiol; 2010 Oct; 225(1):84-91. PubMed ID: 20648626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria.
    Bernardini G; Leone G; Millucci L; Consumi M; Braconi D; Spiga O; Galderisi S; Marzocchi B; Viti C; Giorgetti G; Lupetti P; Magnani A; Santucci A
    J Cell Physiol; 2019 May; 234(5):6696-6708. PubMed ID: 30341892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional interventions for patients with alkaptonuria: A minireview.
    Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
    Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on molecular genetics of Alkaptonuria (AKU).
    Zatkova A
    J Inherit Metab Dis; 2011 Dec; 34(6):1127-36. PubMed ID: 21720873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alkaptonuria in Russia.
    Soltysova A; Kuzin A; Samarkina E; Zatkova A
    Eur J Hum Genet; 2022 Feb; 30(2):237-242. PubMed ID: 34504318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative stress and mechanisms of ochronosis in alkaptonuria.
    Braconi D; Millucci L; Bernardini G; Santucci A
    Free Radic Biol Med; 2015 Nov; 88(Pt A):70-80. PubMed ID: 25733348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of alkaptonuria.
    Phornphutkul C; Introne WJ; Perry MB; Bernardini I; Murphey MD; Fitzpatrick DL; Anderson PD; Huizing M; Anikster Y; Gerber LH; Gahl WA
    N Engl J Med; 2002 Dec; 347(26):2111-21. PubMed ID: 12501223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alkaptonuria in Turkey: Clinical and molecular characteristics of 66 patients.
    Kisa PT; Gunduz M; Dorum S; Uzun OU; Cakar NE; Yildirim GK; Erdol S; Hismi BO; Tugsal HY; Ucar U; Gorukmez O; Gulten ZA; Kucukcongar A; Bulbul S; Sari I; Arslan N
    Eur J Med Genet; 2021 May; 64(5):104197. PubMed ID: 33746036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis.
    Braconi D; Laschi M; Amato L; Bernardini G; Millucci L; Marcolongo R; Cavallo G; Spreafico A; Santucci A
    Rheumatology (Oxford); 2010 Oct; 49(10):1975-83. PubMed ID: 20601653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria.
    Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A
    ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy.
    Zaib S; Rana N; Hussain N; Ogaly HA; Dera AA; Khan I
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-generational alkaptonuria in a non-consanguineous family.
    Oexle K; Engel K; Tinschert S; Haas D; Lee-Kirsch MA
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S425-30. PubMed ID: 19096913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.